The serious illness not only threatens the lives of patients but also costs hospitals billions of dollars in treatment and hospital stays. An article in the Star Ledger notes that BD's rights to its MRSA test that is already on the market has come under fire from BioMerieux. The French company alleges that it licensed some of the underlying technology to GeneOhm and has requested arbitration to end the licensing agreement, according to the article.MRSA, which stands for methicillin-resistant Staphylo coccus aureus, is the most dangerous strain of staph, as it is resistant to certain antibiotics.